Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 60,500 shares, a drop of 32.3% from the December 15th total of 89,300 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average trading volume of 1,230,000 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Several research firms have weighed in on THAR. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw started coverage on shares of Tharimmune in a research note on Friday, December 6th. They set a “buy” rating and a $17.00 price objective for the company.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC purchased a new stake in shares of Tharimmune, Inc. (NASDAQ:THAR) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned 2.06% of Tharimmune at the end of the most recent reporting period. Institutional investors and hedge funds own 1.16% of the company’s stock.

Tharimmune Trading Up 0.5 %

Shares of THAR stock opened at $2.00 on Friday. The business’s 50 day moving average price is $2.19 and its 200-day moving average price is $2.63. Tharimmune has a fifty-two week low of $1.84 and a fifty-two week high of $7.71.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).